NINDS Paylines

Congressional Funding Status

The Department of Health and Human Services (HHS), including NIH, is operating under the Consolidated Appropriations Act, 2023 (Public Law 117-328), signed by President Biden on December 29, 2022. This law continues government operations through September 30, 2023.

Competing Award Administrative Reductions and Funding Policies

  • Non-Modular R01s will receive a 17.5% administrative cut; modular R01s and most other funding mechanisms are generally awarded with no administrative reduction to the IRG-approved funding level.
  • Salaries, stipends, and Training Funds are limited to the levels published by the NIH. We will reduce budgets when these caps are exceeded.  For additional information, see our salary cap, stipends, and training funds page.
  • No inflationary increases are provided in calculating future year commitments. For more details about this and related funding policies, see our Funding Policies page.

Noncompeting Award Funding Policies

  • When an application is funded, NIH agrees to provide funds over several years (for example, the typical NINDS R01 award is funded for five years).  Therefore, investigators request payment for the next budget period (usually, every year), but these requests do not compete with other applications. NINDS will pay FY23 non-competing continuation awards at their full committed level as shown in the Notice of Award and will restore any cuts made in non-competing awards paid earlier in this fiscal year.


Understanding Your Funding Likelihood 

The tables below provide guidelines to applicants trying to assess their likelihood of funding.  There are a few important points of note that applicants must keep in mind when reviewing this information:

exclamation
Key Points

Applications with a Percentile Score 

This table applies to applications receiving a percentiled score. While a score within the paylines shown in the table below suggests a high likelihood of funding, it is not a guarantee; there are rare circumstances where an application within the payline is not funded. 

 

Applicant has >$2M in NIH Funding^ 

Standard 

Early Stage Investigator (ESI

AD/ADRD*

AD/ADRD* ESI

R03 

7% 

14% 

N/A

25%

N/A

R15 

7% 

14% 

N/A

25%

N/A

R21 

7% 

14% 

N/A

25%

N/A

R01 

7% 

14% 

25% 

25% 

30% 

^ Applications with greater than $2 million in NIH funding are subject to Special Council Review.

*For AD/ADRD applications, NINDS follows the same payline as NIA. Please see the NIA Funding Line Policy for more information. 


Non-percentiled applications 

This table applies to applications receiving only a priority score. There are no paylines for non-percentiled applications; rather, applications are individually considered and assessed for portfolio balance based on funds available. The table below is intended to give investigators an indication of their likelihood of funding based on recent trends. It is not intended to suggest that funding at a particular score is guaranteed. 

 

SBIR/STTR
  Most applications funded (>75%) Some applications funded Few applications funded
R41 ≤ 25  26 - 35  > 35 
R42 ≤ 25  26 - 30  > 30 
R43 ≤ 25  26 - 30  > 30 
R44 ≤ 22  23 - 30  > 30 
SB1 ≤ 22  23 - 30  > 30 
U44 ≤ 25  26 - 30  > 30 
 
Fellowships, Training, Career Development, Research Education
  Most applications funded (>75%) Some applications funded Few applications funded
F30 ≤ 30  31 - 35  > 35 
F31 ≤ 20  21 - 26  > 26 
F32 ≤ 30  31 - 37  > 37 
F99 ≤ 35  36 - 40  > 40 
K01 ≤ 30  31 - 45  > 45 
K08 ≤ 30  31 - 40  > 40 
K23 ≤ 30  31 - 37  > 37 
K99 ≤ 30  31 - 37  > 37 
R25 ≤ 30  31 - 40  > 40 
T32 ≤ 30  31 - 35  > 35 

 

Other Research Grants
  Most applications funded (>75%) Some applications funded Few applications funded
P01 ≤ 25  26 - 30  > 30 
P50 ≤ 25  26 - 30  > 30 
R34 ≤ 30  31 - 40  > 40 
R35 ≤ 25  26 - 30  > 30 
R61/R33 ≤ 25  26 - 30  > 30 
U01 ≤ 25  26 - 30  > 30 
U19 ≤ 30  31 - 40  > 40 
U54 ≤ 25  26 - 30  > 30 
UG3/UH3 ≤ 30  31 - 35  > 35